NCT07714382已完成不适用
Survival Outcomes of Residual Disease in Patients With Triple-Negative Breast Cancer Following Neoadjuvant Therapy: A Retrospective Cohort Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Disease free survival
研究概览
简要总结
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with a poor prognosis. Although neoadjuvant therapy improves outcomes in patients who achieve a pathological complete response, the presence of residual disease after treatment remains associated with an increased risk of recurrence and death. This retrospective cohort study aims to evaluate the survival outcomes of patients with residual disease following neoadjuvant therapy for TNBC and to assess the association between clinicopathological characteristics and survival outcomes, including disease-free survival and overall survival
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female patients aged ≥18 years. Histologically confirmed triple-negative breast cancer (TNBC). Received standard neoadjuvant systemic therapy. Underwent definitive breast surgery after completion of neoadjuvant therapy. Availability of postoperative pathological assessment documenting residual disease or pathological complete response (pCR).
- •Complete clinical, pathological, treatment, and follow-up data available in the medical records.
排除标准
- •Patients with metastatic disease at initial diagnosis. Patients who did not complete neoadjuvant therapy or did not undergo definitive surgery.
- •Patients with incomplete or missing essential clinical, pathological, or follow-up data.
- •Patients with a history of another primary malignancy that could affect survival analysis.
结局指标
主要结局
Disease free survival
时间窗: Up to 3 years
次要结局
未报告次要终点
研究者
Asmaa Abdelfattah Kassem
Resident doctor of oncology
Sohag University
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and ImagingNCT07478705Sunnybrook Health Sciences Centre30
尚未招募
1 期
FMT in Triple Negative Breast Cancer Guided by ctDNABreast CancerNCT07292142Jewish General Hospital125
尚未招募
不适用
Real-Life Use of Pembrolizumab for patients With Breast Cancer.CTRI/2026/01/101797Tata Memorial Centre200
招募中
2 期
Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast CancerBreast CancerNCT07401537Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University416
招募中
不适用
Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant ImmunotherapyNCT07311083Kliniken Essen-Mitte60